Solventum Corp Q4 FY2025 earnings call

Brian highlighted that Solventum closed 2025 with solid momentum, formally launched long-range plans, built an experienced leadership team, revamped innovation process, restructured global sales organization, and completed various strategic moves. He also mentioned the progress in separation from 3M, ERP deployments, supply chain changes, and the Acera acquisition. Wade discussed separation activities, Q4 and full-year financial performance, including sales, gross margins, operating expenses, and the 2026 guidance.

MedSurg delivered $1.2 billion in sales, an increase of 3.2% on an organic basis. Within MedSurg, advanced wound care business grew 1.7%, infection prevention and surgical solutions delivered 4.2% growth. Dental solution segment delivered 343 million in sales, an increase of 5.9% on an organic basis. HIS segment contributed with 348 million in sales, an increase of 3.2% on an organic basis.

Top line: organic sales growth range of 2 to 3 percent, translating to 3 to 4 percent excluding 100 basis point impact of SKU exits, with Acera acquisition contributing to reported growth and foreign exchange expected to provide a 100 basis point tailwind. Operating margins: estimate of 21% to 21.5%, expanding from 20.5% in 2025, driven by sales leverage, programmatic savings, and Transform for the Future program. Earnings per share: range of $6.40 to $6.60. Free cash flow: approximately $200 million in 2026, closer to $1 billion excluding separation and divestiture costs.

Potential impact of new tariffs within a similar range as previous, remaining 10% of TSAs to be handled in 2027 with some supply chain and rebranding work, and the contractual option for 3M to step up raw material costs in 2027.

Q: On margins and 2026 guidance, A: Margins in Q4 had one-time nature, 2026 operating margin expansion driven by sales leverage, programmatic savings, and Transform for the Future.

Q: On healthcare IT and AI, A: AI seen as an opportunity, used for autonomous coding with vast proprietary rules and data.

Q: On first quarter call outs, A: Q1 has tough comp, sales headwind, lower operating margin, seasonal gross margin headwind.

Q: On dental strong outperformance, A: Driven by new products and backorder recovery, stable to slightly improving market.

Q: On Transform for the Future, A: Multi-year program, start to benefit in 2026, majority benefits in 2027 and beyond.

Q: On HIS business guardrails, A: Long contracts, switching costs, proprietary rules and algorithms.

Q: On Acera, A: In a growing market, healthy double-digit grower, profitable.

Q: On dental dynamic in other segments, A: New products launched in MedSurg and HIS.

Q: On buyback, A: Offsetting stock-based comp dilution, opportunity to purchase more shares.

Q: On organic revenue guidance across segments, A: All segments expected to improve, MedSurg and IPSS more impacted by SKU.

Q: On management structure change, A: Heather as chief commercial officer, strong operator.

Q: On ERP and volume, A: ERPs to be done by end of 2026, volume hard to predict.

Q: On pricing, A: Expecting plus minus 1% range.

Q: On M&A strategy, A: Continued lever for value creation, mission-centric, attractive markets.

Q: On TSAs and remaining 10%, A: Mostly separation work done in 2026, some rebranding and supply chain in 2027, raw material cost option with intellectual property ownership.